Literature DB >> 21875632

Universal peptide vaccines - optimal peptide vaccine design based on viral sequence conservation.

Nora C Toussaint1, Yaakov Maman, Oliver Kohlbacher, Yoram Louzoun.   

Abstract

Rapidly mutating viruses such as the hepatitis C virus (HCV), the human immunodeficiency virus (HIV), or influenza viruses (Flu) call for highly effective universal peptide vaccines, i.e. vaccines that do not only yield broad population coverage but also broad coverage of various viral strains. The efficacy of such vaccines is determined by multiple properties of the epitopes they comprise. Beyond the specific properties of each epitope, properties of the corresponding source antigens are of great importance. If a response is mounted against viral proteins with a low copy number within the cell or against proteins expressed very late, this response may fail to induce lysis of the infected cells before budding can take place. We here propose a novel methodology to optimize the epitope composition and assembly in order to induce maximum protection. In order for a peptide vaccine to yield the best possible universal protection, several conditions should be met: (a) an optimal choice of target antigens, (b) an optimal choice of highly conserved epitopes, (c) maximum coverage of the target population, and (d) the proper ordering of the epitopes in the final vaccine to ensure favorable cleavage. We propose a mathematical formalism for epitope selection and ordering that balances the constraints imposed by these different conditions. Focusing on HCV, HIV, and Flu, we show that not all of the conditions can be satisfied for all viruses. Depending on the virus, different constraints are harder to fulfill: for Flu, the conservation constraint is violated first, while for HIV, it is difficult to focus the response at the optimal target antigens. The proposed methodology can be applied to any virus to assess the feasibility of optimally combining the above-mentioned constraints.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875632     DOI: 10.1016/j.vaccine.2011.07.132

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.

Authors:  Patricio Oyarzún; Bostjan Kobe
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Graph-theoretical formulation of the generalized epitope-based vaccine design problem.

Authors:  Emilio Dorigatti; Benjamin Schubert
Journal:  PLoS Comput Biol       Date:  2020-10-23       Impact factor: 4.475

Review 3.  Current treatment of hepatitis C-associated rheumatic diseases.

Authors:  Clodoveo Ferri; Marco Sebastiani; Alessandro Antonelli; Michele Colaci; A Manfredi; Dilia Giuggioli
Journal:  Arthritis Res Ther       Date:  2012-06-25       Impact factor: 5.156

4.  EpiToolKit--a web-based workbench for vaccine design.

Authors:  Benjamin Schubert; Hans-Philipp Brachvogel; Christopher Jürges; Oliver Kohlbacher
Journal:  Bioinformatics       Date:  2015-02-20       Impact factor: 6.937

Review 5.  T cell responses to viral infections - opportunities for Peptide vaccination.

Authors:  Sietske Rosendahl Huber; Josine van Beek; Jørgen de Jonge; Willem Luytjes; Debbie van Baarle
Journal:  Front Immunol       Date:  2014-04-16       Impact factor: 7.561

6.  FRED 2: an immunoinformatics framework for Python.

Authors:  Benjamin Schubert; Mathias Walzer; Hans-Philipp Brachvogel; András Szolek; Christopher Mohr; Oliver Kohlbacher
Journal:  Bioinformatics       Date:  2016-02-26       Impact factor: 6.937

7.  Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series.

Authors:  Sultana Abdulaziz; Hussein Halabi; Mohammed A Omair; Suzan Attar; Abdullah Alghamdi; Mohammed Shabrawishi; Abdulwahab Neyazi; Haneen Alnazzawi; Nuha Meraiani; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2017-09-01

8.  Combination of highly antigenic nucleoproteins to inaugurate a cross-reactive next generation vaccine candidate against Arenaviridae family.

Authors:  Kazi Faizul Azim; Tahera Lasker; Rahima Akter; Mantasha Mahmud Hia; Omar Faruk Bhuiyan; Mahmudul Hasan; Md Nazmul Hossain
Journal:  Heliyon       Date:  2021-05-19

Review 9.  Immunoinformatics and epitope prediction in the age of genomic medicine.

Authors:  Linus Backert; Oliver Kohlbacher
Journal:  Genome Med       Date:  2015-11-20       Impact factor: 11.117

10.  Designing string-of-beads vaccines with optimal spacers.

Authors:  Benjamin Schubert; Oliver Kohlbacher
Journal:  Genome Med       Date:  2016-01-26       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.